C07K 14/085
Picornaviridae
Official title: Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
C07K14/085 (Picornaviridae) appears on 17 US grants and 29 published applications in this corpus.
Search patents in C07K- Granted patents
- 17
- Published applications
- 29
- Assignees
- 20
- Inventors
- 70
- Latest grant
- 18 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 3 |
| 2017 | 0 | 0 |
| 2018 | 2 | 3 |
| 2019 | 3 | 5 |
| 2020 | 0 | 2 |
| 2021 | 3 | 4 |
| 2022 | 4 | 3 |
| 2023 | 2 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered Hansenula fungi efficiently expressing CA10 virus-like particles and uses thereof18 Mar 2025US 12,251,435 B2Beijing Minhai Biotechnology Co., Ltd.
- Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins19 Sep 2023US 11,759,512 B2Medicago Inc.
- T cell receptors that bind to NY-ESO-1 and methods of use thereof28 Mar 2023US 11,613,764 B2MiNK Therapeutics, Inc.
- Composite polypeptide monomer, aggregate of said composite polypeptide monomer having cell penetration function, and norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration and having said aggregate as effective component thereof6 Dec 2022US 11,517,616 B2Denka Company Limited
- Synthetic polypeptide epitope based vaccine composition15 Mar 2022US 11,273,215 B2Bharat Biotech International Limited
- Gene sequence construct used for treatment of central nervous system diseases30 Apr 2026US 2026/0117234 A1
- Virus-like particle containing capsid proteins connected by linker19 Jun 2025US 2025/0197454 A1Denka Company Limited
- Rna replicon for improving gene expression and use thereof19 Dec 2024US 2024/0417751 A1South China University of Technology
- T cell receptors that bind to ny-eso-1 and methods of use thereof28 Mar 2024US 2024/0102044 A1MiNK Therapeutics, Inc.
- Immunogenic Human Rhinovirus (HRV) Composition19 Oct 2023US 2023/0330208 A1Biological Mimetics, Inc.
Most cited
By later US patents
- Re-directed immunotherapy4US 9,402,916 B2The University of Birmingham · 2016
- Immunogenic human rhinovirus (HRV) compositions4US 9,872,899 B2Biological Mimetics, Inc. · 2018
- Re-directed immunotherapy3US 9,358,282 B2The University of Birmingham · 2016
- Re-directed immunotherapy2US 11,236,131 B2The University of Birmingham · 2022
- Re-directed immunotherapy1US 10,287,321 B2The University of Birmingham · 2019